Single and Multiple Ascending Dose Study of KN-002

• Status: Recruiting
• Trial end date: 2022-05-30
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase 1, randomized, double-blinded, placebo controlled study. The study consists of 2 parts: Part 1 is a single ascending dose (SAD) study in healthy volunteers; Part 2 is a multiple ascending dose (MAD) study in subjects with stable, mild asthma

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Kinaset Therapeutics Inc

Criteria

Inclusion Criteria:

• Male or female, 18 - 55 years old

• Willing and able to give informed consent and comply with the study

• Body mass index (BMI) 18 to 32 kg/m2 and weighs at least 50 kg

• Women of child bearing potential must have a negative pregnancy test and use a highly efficient birth control method

• Pre-bronchodilator FEV1 ≥ 70 and ≥80% for Part 1 and Part 2 participants, respectively

Exclusion Criteria:

• Clinically significant laboratory test abnormalities

• Clinically significant abnormal blood pressure and/or pulse rate

• Resting ECG clinically significant abnormalities

• Respiratory tract infection within 6 weeks of screening

• Positive test for active COVID-19 within 2 days prior to administration of IMP